NICOX
NicOx is a biopharmaceutical company, engages in the development and commercialization of nitric oxide (NO)-donating drugs primarily for inflammation and cardio-metabolic diseases. The company's primary products candidates include Naproxcinod, a Phase III product candidate for the treatment of osteoarthritis; and NCX 6560, a NO-donating compound for the treatment of cardiovascular diseases, which is in phase I clinical trials. Its product portfolio comprise PF-03187207 for the treatment of glauc... oma, TPI 1020 for the treatment of respiratory disorders, and NCX 1510 for allergic rhinitis, which are in Phase II clinical trials; and NO-donating antihypertensives, which is in phase I clinical trials for the treatment of hypertension. The company's product pipeline also include NCX 1047, which is in preclinical stage of development for treating a range of skin disorders, such as atopic dermatitis, psoriasis, and seborrheic dermatitis; and NO-donors for diabetic retinopathy, cardiometabolic, inflammation, and pain. It has research and co-development agreement with Orexo AB to identify and develop compounds for the treatment of airway diseases; license and development agreement with TOPIGEN Pharmaceuticals Inc. The company also has agreements with Grupo Ferrer Internacional SA for the research, development, and marketing of NO-donating anti-inflammatory drugs for the treatment of dermatological diseases; Pfizer Inc to identify nitric oxide-donating compounds for diabetic retinopathy; and Merck & Co., for the development of new antihypertensive drugs using NicOx' nitric oxide-donating technology. NicOx S.A. was founded in 1996 and is headquartered in Sophia Antipolis, France.
NICOX
Social Links:
Industry:
Biotechnology Health Care Medical Device
Founded:
1996-01-01
Address:
Valbonne, Provence-Alpes-Cote D'Azur, France
Country:
France
Website Url:
http://www.nicox.com
Total Employee:
51+
Status:
Active
Contact:
33 4 97 24 53 00
Email Addresses:
[email protected]
Total Funding:
149 M USD
Technology used in webpage:
Domain Not Resolving Person Schema Ubuntu Java EE Apple Whitelist 3 To 9 CcTLD Redirects Moodle
Similar Organizations
Almirall
Almirall is an international pharmaceutical company based on innovation and committed to health, headquartered in Barcelona, Spain.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2014-09-16 | Doliage | Doliage acquired by NicOx | 5 M EUR |
| 2014-07-02 | Aciex Therapeutics | Aciex Therapeutics acquired by NicOx | 120 M USD |
| 2013-12-06 | EuPharmed | EuPharmed acquired by NicOx | N/A |
Key Employee Changes
| Date | New article |
|---|---|
| 2021-12-13 | Nicox Appoints Doug Hubatsch as new Chief Scientific Officer to lead Clinical and Non-clinical Development |
Official Site Inspections
http://www.nicox.com Semrush global rank: 4.69 M Semrush visits lastest month: 2.05 K
- Host name: 45.92.108.78
- IP address: 45.92.108.78
- Location: Switzerland
- Latitude: 47.1449
- Longitude: 8.1551
- Timezone: Europe/Zurich
More informations about "NicOx"
Nicox - Visible Science
Nicox develops innovative therapeutics to help maintain vision and improve ocular healthSee details»
About Us - Nicox
Nicox is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. The lead program of Nicox’s ophthalmic pipeline, NCX 470, …See details»
NicOx - Crunchbase Company Profile & Funding
Nicox is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. NicOx may be growing as indicated by the financial results …See details»
2022 ANNUAL REPORT - Nicox
Nicox S.A. is an ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Pipeline of products and drug candidatesSee details»
NicOx - Wikipedia
Nicox S.A. is a French ophthalmology company developing treatments to maintain vision and improve ocular health. Nicox is headquartered in Sophia Antipolis, France, and its Chairman and CEO is Michele Garufi. Nicox is listed on Euronext Paris (Compartment B: Mid-Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. Its pipeline includes three progr…See details»
Nicox - LinkedIn
Maintain vision and improve ocular health | Nicox is an international ophthalmic R&D company, aiming to build a diversified portfolio of therapeutic products addressing the needs of eyecare...See details»
Nicox — New governance structure - Edison Group
May 17, 2022 · Nicox has announced a new governance structure that will separate the functions of CEO and chairman. Andreas Segerros, an experienced global pharma executive, will …See details»
Nicox - Edison Group
France-based Nicox develops therapeutics for the treatment of ocular conditions. Lead candidate NCX-470 is in Phase III studies for the treatment of glaucoma and it is advancing NCX-4251 …See details»
News and Events - Nicox
Sep 4, 2024 · Nicox Announces Publication of the Adaptive Design Period of the NCX 470 Mont Blanc Phase 3 TrialSee details»
Nicox Launches New Corporate & Investor Website - GlobeNewswire
Oct 4, 2021 · Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced the launch of its redesigned corporate and investor website.See details»
NICOX - VentureRadar
Nicox is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. We have developed a leading scientific and strategic …See details»
NicOx - Contacts, Employees, Board Members, Advisors & Alumni
Nicox is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health.See details»
Nicox - LinkedIn
Nicox is an international ophthalmic R&D company, aiming to build a diversified portfolio of therapeutic products addressing the needs of eyecare practitioners and patients around the …See details»
Nicox Company Profile 2024: Stock Performance & Earnings
Nicox SA is an international company specializing in ophthalmology developing solutions aimed at maintaining vision and improving eye health. The company's program in clinical development …See details»
Corporate Presentation - nicox.com
Jun 3, 2022 · Nicox SA provides links to Internet sites as a convenience to users, and access to any Internet sites linked to or mentioned in this presentation is at your own risk. 3 Nicox at a …See details»
NicOx Company Profile - Office Locations, Competitors, Revenue …
NicOx S.A. was founded in 1996 and is headquartered in Sophia Antipolis, France. NicOx has 5 employees across 3 locations and €6.9 m in annual revenue in FY 2023. See insights on …See details»
Nicox SA, ALCOX:PAR profile - FT.com - Financial Times
Nov 11, 2024 · Nicox SA (ALCOX:PAR) company profile with history, revenue, mergers & acquisitions, peer analysis, institutional shareholders and more.See details»
Investors - Financial and Regulatory Information - Nicox
Nicox is committed to presenting itself to the financial and investor community in the most transparent way. This section contains information provided for under article 221-1 of the …See details»
Nicox - Overview, News & Similar companies | ZoomInfo.com
Nicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is …See details»
Annual Reports Archive - Nicox
Apr 10, 2024 · All the Annual Reports listed below are available in PDF (in French)See details»